Chemotherapy-induced damage to ovary: Mechanisms and clinical impact

Future Oncology

Volumn 12, Issue 19, 2016, Pages 2333-2344

  Bedoschi, Giuliano ^a,b,c   Navarro, Paula Andrea ^c   Oktay, Kutluk ^a,b  

^a Innovation Institute for Fertility and in Vitro Fertilization   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

anti Mullerian hormone; antral follicle count; chemotherapy; fertility preservation; follicle stimulating hormone; ovarian aging; ovarian damage; ovarian reserve

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ESTROGEN; FOLLITROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR;

ADVERSE DRUG REACTION; AGING; APOPTOSIS; CHEMOTHERAPY INDUCED OVARY DAMAGE; ECHOGRAPHY; FEMALE; FEMALE FERTILITY; HISTOLOGY; HUMAN; NONHUMAN; OVARIAN RESERVE; OVARY BLOOD FLOW; OVARY DISEASE; OVARY FOLLICLE; OVARY FUNCTION; PRIORITY JOURNAL; REVIEW; STROMA CELL; COMPLICATION; DRUG EFFECTS; FERTILITY; FERTILITY PRESERVATION; INFERTILITY, FEMALE; METABOLISM; NEOPLASMS; OVARY; PATHOLOGY; PATHOPHYSIOLOGY; RISK;

AGING; ANTINEOPLASTIC AGENTS; BIOMARKERS; FEMALE; FERTILITY; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; OVARIAN FOLLICLE; OVARIAN RESERVE; OVARY; RISK;

EID: 84989248955     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2016-0176     Document Type: Review

References (71)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. doi:10.3322/caac.21332 (2016) (Epub ahead of print).
2. Tschudin S, Bitzer J. Psychological aspects of fertility preservation in men and women affected by cancer and other life-threatening diseases. Hum. Reprod. Update 15(5), 587-597 (2009).
3. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil. Steril. 99(1), 37-43 (2013).
4. Bedoschi G, Oktay K. Current approach to fertility preservation by embryo cryopreservation. Fertil. Steril. 99(6), 1496-1502 (2013).
5. Oktay K, Bedoschi G, Pacheco F, Turan V, Emirdar V. First pregnancies, live birth, and in vitro fertilization outcomes after transplantation of frozen-banked ovarian tissue with a human extracellular matrix scaffold using robot-assisted minimally invasive surgery. Am. J. Obstet. Gynecol. 214(1), 94 e91-99 (2016).
6. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS ONE 5(1), e8772 (2010).
7. Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 428(6979), 145-150 (2004).
8. Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapyinduced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY) 3(8), 782-793 (2011).
9. Familiari G, Caggiati A, Nottola SA, Ermini M, Di Benedetto MR, Motta PM. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkins disease. Hum. Reprod. 8(12), 2080-2087 (1993).
10. Himelstein-Braw R, Peters H, Faber M. Morphological study of the ovaries of leukaemic children. Br. J. Cancer 38(1), 82-87 (1978).
11. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 110(10), 2222-2229 (2007).
12. Morita Y, Perez GI, Paris F et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat. Med. 6(10), 1109-1114 (2000).
13. Paris F, Perez GI, Fuks Z et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat. Med. 8(9), 901-902 (2002).
14. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum. Reprod. 19(6), 1294-1299 (2004).
15. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 67(21), 10159-10162 (2007).
16. Titus S, Oktay K. Mechanisms of chemotherapy-induced primordial follicle death in human. Presented at: Society for the Study of Reproduction 2014. Grand Rapids, MI, USA, 19-23 July 2014 (Abstract 325796).
17. Oktay K, Turan V, Titus S, Stobezki R, Liu L. BRCA mutations, DNA repair deficiency, and ovarian aging. Biol. Reprod. 93(3), 67 (2015).
18. Marcello MF, Nuciforo G, Romeo R et al. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment. Cancer 66(10), 2099-2104 (1990).
19. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J. Clin. Oncol. 4(9), 1405-1417 (1986).
20. Bar-Joseph H, Ben-Aharon I, Tzabari M, Tsarfaty G, Stemmer SM, Shalgi R. In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels. PLoS ONE 6(9), e23492 (2011).
21. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer 55(10), 2364-2372 (1985).
22. Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS ONE 6(4), e19475 (2011).
23. Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J. Clin. Oncol. 24(24), 4044-4046 (2006).
24. Kalich-Philosoph L, Roness H, Carmely A et al. Cyclophosphamide triggers follicle activation and burnout; AS101 prevents follicle loss and preserves fertility. Sci. Transl. Med. 5(185), 185ra162 (2013).
25. Durlinger AL, Kramer P, Karels B et al. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary. Endocrinology 140(12), 5789-5796 (1999).
26. Kerr JB, Hutt KJ, Cook M et al. Cisplatininduced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat. Med. 18(8), 1170-1172; author reply 1172-1174 (2012).
27. Gonfloni S, Di Tella L, Caldarola S et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapyinduced death. Nat. Med. 15(10), 1179-1185 (2009).
28. Kujjo LL, Chang EA, Pereira RJ et al. Chemotherapy-induced late transgenerational effects in mice. PLoS ONE 6(3), e17877 (2011).
29. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum. Reprod. 16(4), 632-637 (2001).
30. Kerr JB, Hutt KJ, Michalak EM et al. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol. Cell 48(3), 343-352 (2012).
31. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update 7(6), 535-543 (2001).
32. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkins disease. Cancer 52(6), 988-993 (1983).
33. Sklar CA, Mertens AC, Mitby P et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J. Natl Cancer Inst. 98(13), 890-896 (2006).
34. Tarlatzis BC, Zepiridis L. Perimenopausal conception. Ann. NY Acad. Sci. 997 93-104 (2003).
35. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update 12(6), 685-718 (2006).
36. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Folliclestimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil. Steril. 51(4), 651-654 (1989).
37. Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil. Steril. 55(4), 784-791 (1991).
38. Hall JE, Welt CK, Cramer DW. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum. Reprod. 14(2), 409-415 (1999).
39. Knauff EA, Eijkemans MJ, Lambalk CB et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J. Clin. Endocrinol. Metab. 94(3), 786-792 (2009).
40. Muttukrishna S, Mcgarrigle H, Wakim R, Khadum I, Ranieri DM, Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG 112(10), 1384-1390 (2005).
41. Durlinger AL, Visser JA, Themmen AP. Regulation of ovarian function: the role of anti-Mullerian hormone. Reproduction 124(5), 601-609 (2002).
42. Weenen C, Laven JS, Von Bergh AR et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol. Hum. Reprod. 10(2), 77-83 (2004).
43. Kevenaar ME, Meerasahib MF, Kramer P et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 147(7), 3228-3234 (2006).
44. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy C, Englert Y. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 22(7), 1837-1840 (2007).
45. Penarrubia J, Fabregues F, Manau D et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist -gonadotropin treatment. Hum. Reprod. 20(4), 915-922 (2005).
46. Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimullerian hormone. Fertil. Steril. 99(7), 1825-1830 (2013).
47. Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod. Biol. Endocrinol. 12, 26 (2014).
48. Nielsen SN, Andersen AN, Schmidt KT et al. A 10-year follow up of reproductive function in women treated for childhood cancer. Reprod. Biomed. Online 27(2), 192-200 (2013).
49. Nelson SM. Biomarkers of ovarian response: current and future applications. Fertil. Steril. 99(4), 963-969 (2013).
50. Frattarelli JL, Levi AJ, Miller BT, Segars JH. A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles. Fertil. Steril. 80(2), 350-355 (2003).
51. Hendriks DJ, Mol BW, Bancsi LF, Te Velde ER, Broekmans FJ. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil. Steril. 83(2), 291-301 (2005).
52. Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum. Reprod. 18(11), 2368-2374 (2003).
53. Lie Fong S, Laven JS, Hakvoort-Cammel FG et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum. Reprod. 24(4), 982-990 (2009).
54. Van Beek RD, Van Den Heuvel-Eibrink MM, Laven JS et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkins lymphoma during childhood. J. Clin. Endocrinol. Metab. 92(10), 3869-3874 (2007).
55. Lie Fong S, Lugtenburg PJ, Schipper I et al. Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum. Reprod. 23(3), 674-678 (2008).
56. Lutchman Singh K, Muttukrishna S, Stein RC et al. Predictors of ovarian reserve in young women with breast cancer. Br. J. Cancer 96(12), 1808-1816 (2007).
57. Dillon KE, Sammel MD, Prewitt M et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil. Steril. 99(2), 477-483 (2013).
58. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J. Clin. Oncol. 24(7), 1045-1051 (2006).
59. Gracia CR, Sammel MD, Freeman E et al. Impact of cancer therapies on ovarian reserve. Fertil. Steril. 97(1), 134-140 e131 (2012).
60. Davila AM, Biolchi V, Capp E, Corleta H. Age, anti-mullerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide. J. Ovarian Res. 8(1), 82 (2015).
61. Anderson RA, Wallace WH. AntiMullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer. Fertil. Steril. 99(6), 1469-1475 (2013).
62. Jung M, Shin HJ, Rha SY et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann. Surg. Oncol. 17(12), 3259-3268 (2010).
63. Partridge AH, Ruddy KJ, Gelber S et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94(2), 638-644 (2010).
64. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12(2), 141-147 (2007).
65. Anders C, Marcom PK, Peterson B et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 26(3), 286-295 (2008).
66. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96(5), 1336-1343 (2011).
67. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod. Biomed. Online 20(2), 280-285 (2010).
68. Lawrenz B, Fehm T, Von Wolff M et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma -evaluation by using antimullerian hormone and retrieved oocytes. Fertil. Steril. 98(1), 141-144 (2012).
69. Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J. Assist. Reprod. Genet. 28(7), 651-656 (2011).
70. Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, Oktay K. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum. Reprod. 29(1), 107-113 (2014).
71. Roness H, Kashi O, Meirow D. Prevention of chemotherapy-induced ovarian damage. Fertil. Steril. 105(1), 20-29 (2016).